Barclays raised the firm’s price target on Teladoc (TDOC) to $12 from $10 and keeps an Overweight rating on the shares. The stock was up 12% on a better than feared Q3 print, the analyst tells investors in a research note. The firm tells investors to “buy the last cut.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc Health Reports Q3 2024 Financial Results
- Closing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats
- Teladoc sees FY24 revenue growth % low single digits to mid-single digits y/y
- Teladoc reports Q3 EPS (19c), consensus (27c)
- Teladoc sees Q4 revenue growth 0%-2.5% year-over-year